November 2026
Executive Summary
The longevity market, a subsector of the broader anti-aging market, focused on targeting the biological mechanisms of aging, has transitioned from a niche sector into a rapidly growing industry. While the longevity industry lacks a universally accepted definition, Mordor Intelligence estimates the global longevity market at ~$32B for 2026, and increasing to ~$47B in 2031 (~8.2% CAGR) and defines it as therapies and technologies addressing biological aging and related interventions. Driven by rising consumer demand in proactive health tracking, advances in AI, and the cultural shift towards GLP-1s, private capital investment in longevity biotech and diagnostics has surged.
However, despite strong capital investment and technical progress, the sector faces a challenge clearing regulatory hurdles. Because the FDA does not recognize aging as a treatable condition, commercialization of products and drug developments remain complex and constrained. In response to this, there has been increased activity in the preventive diagnostics and compounded peptides space (peptides such as BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon, which pharmacies prepare in customized form outside the standard drug-approval pathway). Additionally, beyond just human applications, the company Loyal has been developing longevity treatments in the canine space. The industry’s trajectory over the next two to three years will be defined less by funding size or technical developments and more by how upcoming regulatory precedents unfold.
Market Structure
As this sector grows there continues to be strong capital investment. Global venture capital devoted to longevity biotech, diagnostics, and healthspan clinics reached roughly $1.92 billion in 2025, more than double the $837 million invested in 2024.
Longevity companies are split into multiple groups. The first contains high-CAPEX human therapeutics, focused on epigenetic reprogramming and cellular rejuvenation. The main companies in this area are NewLimit, Retro Biosciences, and Life Biosciences. These companies rely heavily on funding from biotech venture capital, pharma partners, and tech founders. This is highlighted by NewLimit’s $435 million Series C in June 2026 (about $3.1 billion post-money, led by Founders Fund), even though the company is still preclinical and plans a first-in-human trial (Endpoints News, 2 June 2026; Fierce Biotech, June 2026). It is also highlighted by Retro Biosciences, which announced an initial close at a $1.8 billion pre-money valuation in May 2026, led by 4P Capital, after STAT reported in December 2025 that it was seeking $5 billion (Retro Biosciences, 22 May 2026; STAT News, 3 Dec. 2025). These companies face long clinical trials and strict FDA guidelines.
The second area is preventive diagnostics and health-data platforms, which includes companies such as Function Health (which raised a $298 million Series B in November 2025 at a $2.5 billion valuation and cut its membership price to $365 a year from $499; Fierce Healthcare, 20 Nov. 2025), Neko Health, and GlycanAge, which are built on recurring testing and subscriptions rather than drug development.
The last category focuses on animal longevity and is built around Loyal, which has raised more than $250 million since its inception. Loyal says that, if approved, its drug LOY-002 would be the first FDA-approved drug for lifespan extension in any species (Business Wire, 11 Feb. 2026). The three groups differ in risk and time to revenue: therapeutics face the longest timelines and the highest capital needs, while diagnostics platforms earn recurring revenue today.
Demand Drivers
While the main catalyst for the growth in the longevity sector is the general desire to live a longer and healthier life, there are two other factors driving the current demand in the longevity market. The first is a cultural shift towards preventive, biomarker-driven health, including wearables and at-home lab testing. This is an industry move away from just treating illness to tracking and optimizing basic health. Due to new technological developments, this is becoming increasingly accessible to the general public. The other is the rapid adoption of GLP-1 drugs. GLP-1s are themselves peptide drugs, but they are approved, prescribed medications, unlike the compounded longevity peptides discussed below. About one in eight U.S. adults (12%) say they are currently taking a GLP-1, and nearly one in five (18%) say they have taken one at some point (KFF, Nov. 2025). Anecdotally, patients who begin a GLP-1 appear to be introduced during this time to body-composition monitoring and biomarker tracking. Media likely plays a role as well, with influencers, targeted advertisements, and commercials pushing GLP-1s, peptides, wearables, and testing.
Regulatory Environment
The central constraint to the anti-aging industry is that the FDA does not currently recognize aging as a treatable condition. Therefore, no drug can be approved specifically for aging, since the issue of aging is not something to currently evaluate a drug against. This affects several aspects of the industry, covered in turn: 1) clinical-trial precedent, 2) compounded peptides, and 3) supplements.
1) On trial precedent, the Targeting Aging with Metformin (TAME) trial was designed to evaluate whether metformin can delay the onset of multiple age-related diseases, potentially establishing a regulatory pathway for therapies targeting the biological processes of aging. The trial’s composite clinical endpoint, encompassing cardiovascular events, cancer, cognitive impairment and mortality, was developed in consultation with the FDA, as documented in scientific publications by the trial’s investigators in 2016 and 2018. However, this consultation did not constitute formal FDA recognition of aging as an approved therapeutic indication. Despite its significance for longevity medicine, TAME has experienced prolonged funding delays, in part because generic drugs like metformin lack patent protection. Although its proposed budget has been reported at approximately $75 million, the amount of additional funding currently required has not been independently established. As of October 2026, publicly available primary sources do not confirm that participant enrollment has commenced.
Loyal’s canine drug, LOY-002, is the furthest along. The FDA has accepted two of the three technical sections required for conditional approval, effectiveness in February 2025 and safety in January 2026 (dvm360, 26 Feb. 2025; Business Wire, 13 Jan. 2026). Manufacturing review remains, followed by an application for expanded conditional approval. FDA acceptance of a section is not approval, and full approval would depend on, among other things, the separate STAY study of about 1,300 dogs over about four years. This would set a potential precedent for anti-aging drugs, though it is targeting the veterinary sphere.
2) The compounded longevity peptides named in the summary, as well as emideltide (which was rejected), have a separate regulatory position, since their status depends on the FDA’s 503A Bulk Drug Substances List (the list of bulk ingredients that pharmacies may legally use when compounding) rather than the drug-approval pathway. In July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six of seven peptides under review for the list. BPC-157, KPV and TB-500 passed 8-6 (with one abstention) and MOTS-c passed 7-5, while emideltide was rejected 7-6. However the PCAC vote is non-binding and the FDA must still decide whether to adopt the recommendations and then complete notice-and-comment rulemaking, during which legal compounding of these peptides remains prohibited, so it remains to be seen how the FDA will navigate this period. If the FDA adopts the recommendations and completes rulemaking, there will be a large push, in both marketing and health areas, to expand peptide access with other players potentially entering the field.
3) Outside of the FDA and general regulation, longevity supplements, including NAD+ products, operate under light oversight through the Dietary Supplement Health and Education Act (DSHEA). NAD+, a coenzyme involved in cellular energy metabolism, is a common example, and these products are regulated as dietary supplements rather than drugs. Under DSHEA, companies may make “structure/function” claims without FDA pre-approval if they include a disclaimer and do not claim to treat disease, and advertising is overseen by the FTC. This limited oversight permits marketing claims that are not yet validated. In February 2026, a systematic review of 113 studies found that oral NAD+ precursors reliably raise affected biomarkers, but the effects on actual health outcomes are mixed and inconclusive. This causes risk for both consumers and companies.
Outlook and Risks
Traditionally the anti-aging industry has centered on cosmetic, aesthetic, and supplement products, and it has been expanded by the longevity market. That segment will be shaped more by regulatory developments than by additional capital or new science. Whether and how quickly the FDA adopts the advisory panel’s July 2026 recommendations on the peptides will determine how much of the compounded-peptide and wellness clinic channel can operate on stable legal footing. If Loyal’s canine drug completes its final technical section and wins expanded conditional approval (full approval would follow only after the multi-year STAY study), it will function as an important segment signal for the entire longevity field, even though the approval would be veterinary. Also, because disclosed capital in the space is concentrated in a small number of companies, a clinical or financial setback at any one of them could disproportionately affect investor sentiment across the category more broadly than the dollar size alone would suggest.
Conclusion
Anti-Aging, specifically around longevity, has grown into a distinct segment of the broader health and wellness industry. But, the next stage of growth will be less defined by consumer demand and capital, and more so by a set of regulatory constraints. How those play out over future months and years will outline more of how the industry is structured than any single funding round or marketing technique.
Glossary
503A: Section of the Federal Food, Drug, and Cosmetic Act covering compounding by state-licensed pharmacies and physicians. Its Bulk Drug Substances List names the ingredients they may use.
CAPEX: Capital expenditure: money spent on facilities, equipment, and long-term development.
Coenzyme: A molecule that helps an enzyme do its work, such as NAD+.
DSHEA: The Dietary Supplement Health and Education Act of 1994, under which supplements are regulated more lightly than drugs.
PCAC: The FDA’s Pharmacy Compounding Advisory Committee, whose votes on compounding are advisory and non-binding.
Works Cited
American Federation for Aging Research. “TAME: Targeting Aging with Metformin.” AFAR, www.afar.org/tame-trial.
“BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics.” Business Wire, 13 Feb. 2024, www.businesswire.com/news/home/20240213546755/en/BioAge-Announces-$170-Million-Oversubscribed-Series-D-Financing-to-Accelerate-Development-of-Obesity-and-Metabolic-Disease-Therapeutics.
“Celebrity-Backed Function Health Lands $298M Series B, Rolls Out Medical Intelligence AI Model for Health Data.” Fierce Healthcare, 20 Nov. 2025, www.fiercehealthcare.com/health-tech/function-health-lands-298m-series-b-rolls-out-medical-intelligence-ai-model-health-data.
“FDA Advisory Committee Votes to Add Popular Peptide BPC-157 to Drug Compounding List.” ABC News, 23 July 2026, https://abcnews.com/Health/fda-advisory-committee-votes-add-popular-peptide-bpc/story?id=134913891.
“FDA Panel Backs Compounded BPC-157, KPV Peptides in Win for RFK Jr.” STAT News, 23 July 2026, www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/.
“Loyal Raises $100M Series C, Led by age1, to Advance the First Canine Longevity Drug.” Business Wire, 11 Feb. 2026, www.businesswire.com/news/home/20260211301175/en/Loyal-Raises-$100M-Series-C-Led-by-age1-to-Advance-the-First-Canine-Longevity-Drug.
“Loyal Receives FDA Acceptance of Safety Package for Senior Dog Lifespan Extension Drug.” Business Wire, 13 Jan. 2026, www.businesswire.com/news/home/20260113476778/en/Loyal-Receives-FDA-Acceptance-of-Safety-Package-for-Senior-Dog-Lifespan-Extension-Drug.
“FDA Clears Safety Step for Loyal’s Senior Dog Longevity Drug.” Longevity.Technology, 14 Jan. 2026, longevity.technology/news/fda-clears-safety-step-for-loyals-senior-dog-longevity-drug/.
Crossley, K. C. “Second Drug for Canine Healthy Lifespan Extension Receives FDA Support.” dvm360, 26 Feb. 2025, www.dvm360.com/view/second-drug-for-canine-healthy-lifespan-extension-receives-fda-support
“NAD⁺ Supplementation for Anti-Aging and Wellness: A PRISMA-Guided Systematic Review of Preclinical and Clinical Evidence.” Ageing Research Reviews, ScienceDirect, Feb. 2026, www.sciencedirect.com/science/article/pii/S1568163726000498.
“New Heights for NewLimit as Anti-Aging Biotech Nabs $435M to Rejuvenate Old Cells.” Fierce Biotech, June 2026, www.fiercebiotech.com/biotech/new-heights-newlimit-anti-aging-biotech-nabs-435m-rejuvenate-old-cells.
“Anti-Aging Biotech NewLimit Raises $435M at $3B+ Valuation.” Endpoints News, 2 June 2026, https://endpoints.news/anti-aging-biotech-newlimit-raises-435m-at-3b-valuation/
“Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford.” KFF, 14 Nov. 2025, www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/.
DeAngelis, Allison. “Aging Startup Retro Bio Chases $5 Billion Valuation.” STAT News, 3 Dec. 2025, www.statnews.com/2025/12/03/aging-startup-retro-bio-chases-5-billion-valuation/.
Retro Biosciences. “Retro Biosciences: Next Phase.” Retro Biosciences, 22 May 2026, www.retro.bio/blog/fundraise-2026.
United States, Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket No. FDA-2025-N-6895, www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026.
“TAME Trial 2026: Current Status, Funding Delays, and What Comes Next for Metformin Anti-Aging Research.” Stacking Years, 18 Mar. 2026, www.stackingyears.com/blog/tame-trial-metformin-2026-status-update.
By Craig Lawson
Managing Director
Clicking some links in this article will take you to websites independent of and unaffiliated with Hyde Park Capital. The information and services provided on these independent sites are not reviewed, guaranteed, or endorsed by Hyde Park Capital or its affiliates. Please keep in mind that these independent sites’ terms and conditions, privacy and security policies, or other legal information may be different.